Hemp oil has never been as popular as other marijuana products. With little to no THC, CBD-rich strains of cannabis don’t deliver the pleasant buzz recreational users seek out in marijuana. In the 1970s, however, scientists found that cannabidiol was effective in reducing seizures. The brain’s endocannabinoid system contains receptors that respond to CBD, producing anticonvulsant effects. Being plant-derived and native to the brain’s own chemistry, CBD is therefore one of the most natural options for seizure treatment available today. Still, not many people took interest in CBD until 2013, when a CNN documentary special, Weed, hosted by the network’s chief medical correspondent, Dr. Sanjay Gupta, highlighted CBD’s effectiveness in combating seizures. Since then, demand for hemp oil products has exploded.
Participants must pay the $400 fee to receive industrial hemp seed through the DEA approved pilot program. Applicants must secure seed orders from DEA approved international seed suppliers. The department will work with the seed suppliers to secure import and export permits to have the seed delivered to the department. Seed costs and shipping are not included in the fee.
When Brandon Krenzler’s daughter Mykayla was diagnosed with a form of childhood leukemia in 2012 at the age of seven, he began researching medical marijuana products that might ease her symptoms and blogging about the results. The next year, he received some samples of Real Scientific Hemp Oil, which he administered to Mykayla. But the oil made her sick.
"Skunk" refers to several named strains of potent cannabis, grown through selective breeding and sometimes hydroponics. It is a cross-breed of Cannabis sativa and C. indica (although other strains of this mix exist in abundance). Skunk cannabis potency ranges usually from 6% to 15% and rarely as high as 20%. The average THC level in coffee shops in the Netherlands is about 18–19%.
In the early 1990s, industrial hemp agriculture in North America began with the Hemp Awareness Committee at the University of Manitoba. The Committee worked with the provincial government to get research and development assistance, and was able to obtain test plot permits from the Canadian government. Their efforts led to the legalization of industrial hemp (hemp with only minute amounts of tetrahydrocannabinol) in Canada and the first harvest in 1998.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Anybody can apply to grow industrial hemp except one who has been convicted of a felony for controlled substance in the past 10 years. Anyone who has been issued a hemp license can grow on the approved growing areas indicated on their application. Licensed industrial hemp can be grown anywhere, indoor or outdoor. The research pilot program allows for any size growing area, from large acre lots to small garden sizes. There are no zoning requirements for a hemp license.
The United Kingdom and Germany resumed commercial production in the 1990s. British production is mostly used as bedding for horses; other uses are under development. Companies in Canada, the UK, the United States, and Germany, among many others, process hemp seed into a growing range of food products and cosmetics; many traditional growing countries still continue to produce textile-grade fibre.
In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines. Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.[24,25]
I am currently going through red skin syndrome/topical steroid withdrawal. The only cure as of now is time(6 months to 3 years) and waiting out horrible eczema-like flares. My main issue is burning/tingling skin that is almost constant. Steroids close off blood vessels and when you stop them they 'wake' up causing this nerve discomfort/pain. I've been smoking medical cannabis for the duration of my recovery(1.5 years) and It's done wonders except that the flare is around my mouth and I'm afraid the smoking is causing more issues.. as well as helping. I need to step up my game and take a different approach. I am wondering how to go about using cbd but I don't know where to start and was wondering if you could help. Thank you
Industrial hemp is from the plant species Cannabis sativa and has been used worldwide to produce a variety of industrial and consumer products. Hemp is a source of fiber and oilseed grown in more than 30 nations. In the United States production is controlled under drug enforcement laws. To produce industrial hemp in the United States the grower must obtain a permit from the Drug Enforcement Agency (DEA).
Did you get an answer for this? I have the exact same scenario. I'm treating my TN with Tegretol, and recently tried CBD. I think I took too much and there are some weird drug interactions with Tegretol and I felt quite stoned....was alone and talking to myself in my head thinking I was Einstein. It freaked me out a bit but I think I took too much. I'm trying lower doses again as recently my TN seems to be resisting the meds, although I have had a lot of emotional stress, which seems to be a trigger. Thanks!! Anna